CN1802179B - 含有哌拉西林和三唑巴坦的注射用组合物 - Google Patents

含有哌拉西林和三唑巴坦的注射用组合物 Download PDF

Info

Publication number
CN1802179B
CN1802179B CN2004800159296A CN200480015929A CN1802179B CN 1802179 B CN1802179 B CN 1802179B CN 2004800159296 A CN2004800159296 A CN 2004800159296A CN 200480015929 A CN200480015929 A CN 200480015929A CN 1802179 B CN1802179 B CN 1802179B
Authority
CN
China
Prior art keywords
pharmaceutical composition
composition
acid
solution
piperacillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CN2004800159296A
Other languages
English (en)
Chinese (zh)
Other versions
CN1802179A (zh
Inventor
J·M·科亨
S·M·沙
C·L·奥夫斯拉格
M·B·法齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings Ltd
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1802179(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Publication of CN1802179A publication Critical patent/CN1802179A/zh
Application granted granted Critical
Publication of CN1802179B publication Critical patent/CN1802179B/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2004800159296A 2003-04-14 2004-04-06 含有哌拉西林和三唑巴坦的注射用组合物 Ceased CN1802179B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14
US60/462,808 2003-04-14
PCT/US2004/010698 WO2004091666A1 (en) 2003-04-14 2004-04-07 Compositions containing piperacillin and tazobactam useful for injection

Publications (2)

Publication Number Publication Date
CN1802179A CN1802179A (zh) 2006-07-12
CN1802179B true CN1802179B (zh) 2011-09-14

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800159296A Ceased CN1802179B (zh) 2003-04-14 2004-04-06 含有哌拉西林和三唑巴坦的注射用组合物

Country Status (34)

Country Link
US (3) US7498312B2 (https=)
EP (1) EP1468697B1 (https=)
JP (1) JP4644659B2 (https=)
KR (1) KR100824554B1 (https=)
CN (1) CN1802179B (https=)
AR (1) AR043863A1 (https=)
AT (1) ATE381947T1 (https=)
AU (1) AU2004229407B2 (https=)
BR (1) BRPI0409450B8 (https=)
CA (1) CA2464258C (https=)
CH (1) CH695185A9 (https=)
CL (1) CL2004000782A1 (https=)
CO (1) CO5700796A2 (https=)
CR (2) CR8035A (https=)
CY (1) CY1108064T1 (https=)
DE (1) DE602004010862T2 (https=)
DK (1) DK1468697T3 (https=)
EC (1) ECSP056100A (https=)
ES (1) ES2298672T3 (https=)
FR (1) FR2853547B1 (https=)
GB (1) GB2400557B (https=)
IL (1) IL171337A (https=)
MX (1) MXPA05010996A (https=)
MY (1) MY139099A (https=)
NO (1) NO20054789L (https=)
NZ (1) NZ543005A (https=)
PL (1) PL1468697T3 (https=)
PT (1) PT1468697E (https=)
RU (2) RU2322980C2 (https=)
SA (1) SA04250119B1 (https=)
SI (1) SI1468697T1 (https=)
TW (1) TWI308069B (https=)
WO (1) WO2004091666A1 (https=)
ZA (1) ZA200508315B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
KR20070110256A (ko) * 2004-10-14 2007-11-16 와이어쓰 유산나트륨 희석제 내에 피페라실린, 타조박탐 및아미노카르복실산을 함유하는 조성물
PT1841432E (pt) * 2004-12-02 2010-10-25 Venus Remedies Ltd Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
BR112013012735B1 (pt) 2010-11-25 2021-11-23 Allecra Therapeutics Gmbh Composição farmacêutica inibidora de ss-lactamase
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
EP3431092A1 (en) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
CN110279698B (zh) 2013-03-15 2022-10-28 默沙东有限责任公司 头孢特咯瓒抗生素组合物
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
KR20170067709A (ko) * 2014-10-08 2017-06-16 사와이세이야쿠 가부시키가이샤 동결 건조 제제의 제조 방법
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
AU2017242135A1 (en) * 2016-03-31 2017-11-02 Wockhardt Limited Antibacterial compositions
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法
WO2025253343A1 (en) * 2024-06-06 2025-12-11 Chandan Chopra AN ANTIBIOTIC COMPOSITION OF A PENICILLIN, A β-LACTAMASE INHIBITOR AND AN ION-CHELATING AGENT
CN119367287B (zh) * 2024-12-27 2025-03-28 成都硕德药业有限公司 一种重酒石酸去甲肾上腺素注射液及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
WO2004098643A1 (en) * 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection

Also Published As

Publication number Publication date
FR2853547A1 (fr) 2004-10-15
DE602004010862T2 (de) 2009-01-02
EP1468697A1 (en) 2004-10-20
DK1468697T3 (da) 2008-04-14
JP4644659B2 (ja) 2011-03-02
WO2004091666A8 (en) 2005-11-10
ZA200508315B (en) 2008-04-30
TW200503758A (en) 2005-02-01
KR20060014375A (ko) 2006-02-15
CH695185A5 (fr) 2006-01-13
NZ543005A (en) 2009-03-31
MXPA05010996A (es) 2005-12-12
CL2004000782A1 (es) 2005-03-04
US20090176720A1 (en) 2009-07-09
BRPI0409450A (pt) 2006-05-02
WO2004091666A1 (en) 2004-10-28
HK1069775A1 (en) 2005-06-03
RU2007142454A (ru) 2009-05-27
GB0407853D0 (en) 2004-05-12
GB2400557B (en) 2005-06-15
TWI308069B (en) 2009-04-01
NO20054789D0 (no) 2005-10-18
KR100824554B1 (ko) 2008-04-24
ECSP056100A (es) 2006-03-01
CN1802179A (zh) 2006-07-12
AU2004229407B2 (en) 2010-04-22
DE602004010862D1 (de) 2008-02-07
US20060234995A1 (en) 2006-10-19
CY1108064T1 (el) 2014-02-12
BRPI0409450B1 (pt) 2016-07-12
SA04250119B1 (ar) 2008-03-30
CO5700796A2 (es) 2006-11-30
JP2006523695A (ja) 2006-10-19
IL171337A (en) 2011-03-31
MY139099A (en) 2009-08-28
US20110166091A1 (en) 2011-07-07
AU2004229407A1 (en) 2004-10-28
CA2464258A1 (en) 2004-10-14
SI1468697T1 (sl) 2008-04-30
CR8035A (es) 2006-05-30
ES2298672T3 (es) 2008-05-16
RU2005135135A (ru) 2006-06-10
US7498312B2 (en) 2009-03-03
GB2400557A (en) 2004-10-20
CA2464258C (en) 2005-06-07
EP1468697B1 (en) 2007-12-26
PT1468697E (pt) 2008-03-05
CH695185A9 (fr) 2006-02-28
BRPI0409450B8 (pt) 2021-05-25
US7915229B2 (en) 2011-03-29
AR043863A1 (es) 2005-08-17
NO20054789L (no) 2005-12-13
ATE381947T1 (de) 2008-01-15
RU2322980C2 (ru) 2008-04-27
US8133883B2 (en) 2012-03-13
CR9792A (es) 2008-09-23
PL1468697T3 (pl) 2008-05-30
FR2853547B1 (fr) 2006-08-04

Similar Documents

Publication Publication Date Title
CN1802179B (zh) 含有哌拉西林和三唑巴坦的注射用组合物
US6900184B2 (en) Compositions containing pipercillin and tazobactam useful for injection
WO2004098643A1 (en) Compositions containing piperacillin and tazobactam useful for injection
EP2062582B1 (en) Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers
WO2006044600A1 (en) Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent
CN108601730B (zh) 万古霉素的制剂
CN104352454A (zh) 注射用夫西地酸钠粉针剂药物组合物和制法
HK1069775B (en) Compositions containing piperacillin and tazobactam useful for injection
AU2005201499B2 (en) Premixed formulation of piperacillin sodium and tazobactam sodium injection
NZ554077A (en) Compositions containing piperacillin, tazobactam and a aminocarboxylic acid in sodium lactate diluent
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
HK1259054A1 (zh) 万古霉素的制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: New York, United States

Patentee after: Wyeth Holdings Ltd.

Address before: new jersey

Patentee before: WYETH HOLDINGS Corp.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20110914

IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20241114

Decision number of declaring invalidation: 580281

Granted publication date: 20110914

Decision date of declaring invalidation: 20241114

Decision number of declaring invalidation: 582905

Granted publication date: 20110914

Decision date of declaring invalidation: 20241114

Decision number of declaring invalidation: 580270

Granted publication date: 20110914